References
- Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-46
- Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 2012;108:291-302
- Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S
- Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
- Clinicaltrials.gov. Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) (RE-COVER II). http://clinicaltrials.gov/ct2/show/NCT00680186?term=re-Cover+dabigatran&rank=1. Accessed March 3, 2014
- EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
- EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
- Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
- The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15
- Prins MH, Lensing AWA, Bauersachs R, et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21
- Lefebvre P, Laliberté F, Nutescu EA, et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thromb Haemost 2013;110:1288-97
- Amin A, Jing Y, Trocio J, et al. Incremental healthcare burden of bleeding among patients with venous thromboembolism in the US. The International Society on Thrombosis and Haemostasis 60th Annual Scientific and Standardization Committee (SSC) Meeting. Milwaukee, WI, June 23–26, 2014
- Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing. Centers for Medicare and Medicaid Services. Baltimore, MD. http://www.medicarepaymentandreimbursement.com/2013/12/medicare-schedule-update-important.html. Accessed March 3, 2014
- US Department of Labor. Consumer Price Index December 2013. USDL-14-0037. Washington D.C.: Bureau of Labor Statistics US Department of Labor; 2013. http://www.bls.gov/news.release/archives/cpi_01162014.pdf. Accessed March 3, 2014
- Chiong JR, Kim S, Lin J, et al. Evaluation of costs associated with tolvaptan-mediated length of stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ 2012;15:1-9
- Dasta JF, Chiong JR, Christian R, et al. Evaluation of costs associated with tolvaptan- mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hospit Pract 2013;40:1-8
- Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9
- Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74
- Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007;92:199-205
- Analy$ource Online. San Francisco, CA: First Databank Inc.; 2013
- Health Care Costs: A Primer. Menlo Park, CA: Kaiser Family Foundation; 2012. http://kff.org/report-section/health-care-costs-a-primer-2012-report/